E
Washington DC in Fall

SITC21 – What to Watch out for

SITC 2021 Preview

October 22, 2021
E

Endless DDR changes and how we are going beyond PARP inhibitors

A detailed look at Repare's ATR inhibitor data from the TRIPLE meeting

October 15, 2021
E

Coming back full circle

Can a genomic signature help select patients more accurately for DDR therapies?

August 26, 2021
E

Sorting signals from the noise

PARP plus IO and IO combos are becoming all the rage, what can we learn from early signals?

March 5, 2019
E

Are AI and machine learning alive or dead in oncology?

How can AI and ML speed up or improve our drug discovery efforts in oncology R&D?

June 15, 2021
E

An in-depth look at OLYMPIAD in HER2 negative breast cancer

Olaparib is the first PARP to demonstrate a clinical benefit in HER2- breast cancer - what do KOLs really think?

June 12, 2017
E

Novel DDR combinations and regimens that could make a difference

Latest preclinical and clinical news and readouts as well as forthcoming trial presentations to look forward to in the DDR space

August 16, 2019
E

Which early phase agents look promising – or not – ASCO21?

New product development and early phase anti-cancer agents have been very much a focus on BSB (and PSB…

June 6, 2021
E

Is olaparib scaling new heights in OlympiA?

PARP inhibitors move into the adjuvant setting at long last? Say it ain't so!

June 3, 2021
E

ASCO21 Off the Beaten Track Part 2

A look at some hidden gems in the ASCO program and what it all means in terms of the science.

May 27, 2021
E

When PARP and immunotherapy worlds collide

New research is emerging which may have an impact on future trial designs as well as combination partners and even different tumour types.

May 12, 2021
E

The future of breast cancer research

Some key learnings from the ESMO Breast Cancer meeting held last week

May 10, 2021
E

Tooting the DDR horn

Bridging the DDR gap from AACR to ASCO

May 7, 2021
E

AACR21 Preview 5 Promising new developments in the PARP field and beyond

What's hot on the DDR front and PARP inhibitor space at AACR21?

March 25, 2021
E

AACR21 Preview 3 Novel and cool approaches emerging in oncology pipelines

Emerging areas in cool new science around targeted therapies

March 18, 2021
E

Finding success in hard to treat breast cancers

Post SABCS analysis of a key topic and cancer driver

December 15, 2020
E

Notes from a small island

new approaches to applying translational research to the clinic in oncology R&D

November 3, 2020
E

TRIPLE highlights and lowlights in Developmental Therapeutics

The trials and tribulations of targeted agents in developmental therapeutics

October 25, 2020
E

A contrarian view of key cancer trial results

Winners, losers and risers... who goes where in the final analysis?

October 8, 2020
E

A phoenix rises from the ashes

A look at one oncology biotech company's early pipeline and how it fits in with the emerging landscape

September 23, 2020
E

Important learnings from ESMO20

Surprising new developments in early stage breast and metastatic prostate cancers

September 21, 2020
E

ESMO20 Preview 4 – Targeted therapies to watch out for

What to watch out for this weekend in targeted therapies and early stage new product development

September 17, 2020
E

Flying high in the DDR oncology niche

New developments in the DDR niche suggest a whole new approach to tackling solid tumours beyond women's cancers, pancreatic and prostate cancer might be feasible.

May 5, 2020
E

Novel anti-cancer agents to watch out for

A look at five novel anti-cancer agents in early R&D pipelines and what we can learn from their experiences

April 30, 2020
E

AACR20 – Ten New Directions in Early Cancer Drug Development

Ten intriguing novel agents in early development to watch out for

April 23, 2020
E

PARP inhibition in metastatic prostate cancer

What can we learn from the phase 2 trials with PARP inhibitors in mCRPC? Quite a lot, it would seem...

October 9, 2019
E

Crossing the Rubicon

Insights from a US KOL on the phase 3 PROfound trial exploring olaparib in mCRPC

October 8, 2019
E

ESMO19 Day 4 Highlights including the PROfound trial in advanced prostate cancer

Highlights from the PROfound trial in advanced prostate cancer and other stories of interest

September 30, 2019
E

ESMO19 Day 3 Highlights and Commentary

Key findings and commentary on the third day of ESMO

September 29, 2019
E

Highlights of Day 2 at ASCO19

Insights from Day 2 of ASCO19, plus a look at what to expect in the plenary and other sessions today.

June 2, 2019
E

Going beyond PARP inhibitors to improve cancer outcomes

We've heard much about PARP inhibitors but they aren't the only targets in DDR we can hit...

April 11, 2019
E

Picking PARP inhibitors apart

Are the PARPi a class effect or are there real differences between them that may become more apparent in future combo studies?

August 1, 2018
E

An under-appreciated oncology drug class

How can we improve on monotherapy with PARP inhibitors? How do we address primary and acquired resistance?

April 10, 2018
E

Going beyond PARP monotherapies

A look at PARP as it journeys from 1999 to 2017 culminating in a plenary presentation at ASCO

June 13, 2017
E

Going Beyond PARP in DNA Damage Repair

A look a one company's approach to DDR and potential combination opportunities in this niche

May 9, 2017
E

How do we get cancer immunotherapy to work in Prostate Cancer?

A candid look at new approaches being explored in cold tumours using prostate cancer as an example

May 1, 2017
E

Journal Club – February 2017

A look at what we can learn from some recently published new papers in the oncology space.

February 9, 2017
E

How to improve response rates with targeted therapies in oncology

Exploring clinical trials with targeted therapies, including PARP and ATR inhibitors and combination approaches

February 2, 2017
E

Where does rucaparib fit in ovarian cancer?

How does the rucaparib data at ESMO fit in the treatment paradigm and what's next for PARPi?

October 24, 2016
E

What do Myriad Genetics really think of the Niraparib data?

Following the dispute between Tesaro and Myriad on HRD testing, here's Myriad's perspective on the data presented

October 20, 2016
E

What Tesaro aren’t telling you about niraparib

What you need to know about the Tesaro niraparib ovarian cancer data presented at ESMO 2016.

October 8, 2016
E

Biomarin PARP inhibitor talazoparib shows promise in gBRCA Breast Cancer

Biomarin have a good shot on goal with their PARP inhibitor talazoparib in gBRCA breast cancer

January 9, 2015
E

ASCO 2014 What do oncologists think of PARP inhibitors?

With the intense focus on immino-oncology, are targeted agents passe now?

June 11, 2014
E

AbbVie’s PARP inhibitor veliparib is highly active in triple negative breast cancer

The first readout from the I-SPY2 neoadjuvant breast cancer trial comes from the veliparib (PARP) arm.

December 13, 2013